Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JYAXX
ADC Name
WO2022253035A1 ADC-28
Synonyms
WO2022253035A1 ADC 28
   Click to Show/Hide
Organization
Sichuan Kelun Pharmaceutical Co., Ltd.
Drug Status
Investigative
Indication
In total 3 Indication(s)
Colorectal cancer [ICD11:2B91]
Investigative
Gastric cancer [ICD11:2B72]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
Drug-to-Antibody Ratio
7.73
Structure
Antibody Name
19F6_Hu35v1
  Antibody Info 
Antigen Name
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2022253035A1 ADC-28 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
25.67
ug/mL
NCI-N87 cells
Gastric tubular adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 25.67 ug/mL Positive ROR1 expression (ROR1 +++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
References
Ref 1 Antibody drug conjugate, and preparation method therefor and use thereof; 2022-12-08.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.